NEWS
Ensysce Biosciences Announces IRB Approval for Key MPAR Study
Ensysce Biosciences (NASDAQ:ENSC) has received IRB approval for the PF614-MPAR-102 protocol, marking a significant milestone in the clinical development of their FDA-designated Breakthrough Therapy for severe pain relief. This study, supported by a $14 million federal grant, will evaluate the pharmacokinetics of oxycodone and PF614 when co-administered with nafamostat. PF614-MPAR is unique as the only opioid with both abuse and overdose protection to receive Breakthrough Therapy designation. The company plans to initiate the three-part trial immediately, with first data expected in mid-2025. This development brings Ensysce closer to introducing a new generation of safer pain management products.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2329Followers
106Following
24KVisitors
Follow